Is fatty liver reversible?
The short answer
Often, yes. Fat in the liver responds well to weight loss, more activity and less sugar and alcohol. In one well known study, people who lost 10 per cent of their body weight saw the liver inflammation of fatty liver disease resolve in nine out of ten cases, and almost half saw some scarring improve.
Choose your depth
Often, yes. Fat in the liver responds well to weight loss, more activity and less sugar and alcohol. In one well known study, people who lost 10 per cent of their body weight saw the liver inflammation of fatty liver disease resolve in nine out of ten cases, and almost half saw some scarring improve.
Choose Detailed for the fuller picture, or Scientific for mechanisms and study data.
Fatty liver disease affects roughly one in three Indian adults. Most people have no symptoms. Liver fat responds well to lifestyle change.
Weight loss is the most powerful tool
In a study of 293 people with biopsy-proven non-alcoholic steatohepatitis, the more weight people lost over a year, the more their livers improved. Among those who lost 10 per cent or more of their body weight, 90 per cent saw the inflammation resolve and 45 per cent had less scarring.
Even 5 to 7 per cent weight loss reduces liver fat meaningfully.
What else helps
- Regular activity, which reduces liver fat even before weight changes
- Cutting sweetened drinks and refined carbohydrates
- Avoiding or limiting alcohol
- Managing blood sugar, blood pressure and cholesterol
Medicines and supplements
In a large trial, high-dose vitamin E improved liver histology in people without diabetes. Other treatments are being studied. Any medicine or supplement for the liver should be chosen with a doctor, because the right choice depends on the stage of disease and other conditions.
When scarring is advanced
Early fibrosis can improve. Cirrhosis, the most advanced stage, is much less reversible, which is why early detection matters.
Histological endpoints: in Vilar-Gomez et al. (2015), weight loss was an independent predictor of NASH resolution (OR 1.62 per percentage point) and fibrosis regression. Results were observational within a lifestyle programme, but the dose-response relationship was consistent.
PIVENS (Sanyal et al., 2010) randomised 247 non-diabetic adults with NASH to vitamin E 800 IU, pioglitazone 30 mg or placebo for 96 weeks; vitamin E met the composite histological endpoint (43 versus 19 per cent, P = .001, NNT 4.2).
Nomenclature has changed: NAFLD is now increasingly termed metabolic dysfunction-associated steatotic liver disease (MASLD), reflecting its link with insulin resistance. Non-invasive scores such as FIB-4 and elastography are used to stage fibrosis without biopsy.
What we know
- Weight loss of 7 to 10 per cent reliably improves fatty liver.
- Early fibrosis can regress.
- Fatty liver is strongly linked with diabetes and abdominal obesity.
What remains uncertain
- Which people progress to cirrhosis and why.
- The long-term role of supplements.
- How well results from Western trials apply to Indian patients.
The evidence
Related ingredients
Sources
- Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology. 2015;149(2):367-378.
- Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362(18):1675-1685.
- Wah Kheong C, Nik Mustapha NR, Mahadeva S. A randomized trial of silymarin for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2017;15(12):1940-1949.
Last updated 15 October 2026.
This is educational content and does not replace advice from a qualified doctor. If you have symptoms or take medicines, please speak to your doctor before making changes.
